← All trials
NCT05537740
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2022
- Primary completion
- Oct 18, 2026
- Completion date
- May 4, 2027
- First posted
- Sep 13, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 270
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.